I-Mab Announces IND Approval for Its Proprietary TJC4, A Potentially Differentiated CD47 Antibody, to Initiate Clinical Trials in China

BEIJING, June 13, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces that the National Medical Products Administration (NMPA) has...

from PR Newswire: https://ift.tt/2laEQn2